Sequential CAR-T cells for advanced ovarian cancer with CD146 and GPC3
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack ovarian cancer cells that have two specific markers (CD146 and GPC3). It is for people with advanced ovarian cancer who have already tried standard treatments like platinum-based chemotherapy and need new options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced ovarian cancer (including fallopian tube or primary peritoneal cancer) that has come back or stopped responding to standard treatments, including at least one platinum-based chemotherapy.
- A recent tumor sample shows your cancer cells have two specific proteins, CD146 and GPC3 (this is checked by a special lab test).
- You are at least 18 years old, in generally good health (ECOG performance status 0 or 1), and have adequate organ function (liver, kidneys, bone marrow).
- You have at least one tumor that can be measured on a CT scan or other imaging.
- You have not had any prior CAR-T cell therapy targeting CD146 or GPC3, and you do not have active brain metastases, uncontrolled infections, or other serious medical conditions that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CAR-T cells that target a protein called B7H3 found on cancer cells. It is for people with a specific type of ovarian, peritoneal, or fallopian tube cancer that has not responded well to platinum chemotherapy or has come back quickly.
This study tests an experimental therapy called SCT-001 CAR T cells, made from your own immune cells, for ovarian cancer that has not responded to standard treatments. The goal is to see if these engineered cells can find and attack your cancer cells, which could help shrink or control the disease.
This trial tests a new treatment called CAR-T cells that target a protein called CD70 found on some gynecologic cancer cells. It is for people whose cancer has advanced or spread and has not responded to or stopped responding to standard treatments.
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
This trial tests a new type of immunotherapy where your own immune cells are modified to find and attack sarcoma cells that carry markers called CD146 or HER2. It is for people with advanced sarcoma who have already tried standard treatments.
This trial tests a new type of immunotherapy called CAR-T cells for advanced ovarian, uterine, or other gynecological cancers that have not responded to standard treatments. The CAR-T cells are specially designed to target proteins (MUC1, MSLN, PD-L1) found on cancer cells.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.